Sarepta FDA meeting 3rd Q 2024 is in reference to the PPMO drug 5501 with data recently released.
Elevidys gene therapy expanded label response from FDA is next month.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-44
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.1¢ |
Change
0.002(2.53%) |
Mkt cap ! $84.79M | |||
| Open | High | Low | Value | Volume |
| 8.0¢ | 8.1¢ | 7.9¢ | $110.7K | 1.388M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 552412 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 217684 | 2 |
View Market Depth
| Last trade - 16.10pm 18/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |